An additional bispecific, humanized IgG1 antibody that's under investigation is zenocutuzumab (MCLA-128), which acts through two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells through ADCC. MCLA-128 capabilities via a ‘dock and block’ mechanism whereby one arm from the antibody binds HER2 area I and https://www.directivepublications.org/journal-of-clinical-breast-cancer/